Testing JZP926 for juvenile myoclonic epilepsy
Part of Brain & nervous system clinical trials.
This trial tests a new capsule, JZP926, to see if it reduces myoclonic seizures in people with juvenile myoclonic epilepsy (JME). It may offer a new treatment option if you have at least 4 myoclonic seizure days per month and meet other criteria.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 10 years or older.
- You must have a diagnosis of juvenile myoclonic epilepsy (JME).
- You should have at least 4 days per month with myoclonic seizures (quick, jerky muscle twitches).
- You cannot have other seizure types besides generalized tonic-clonic, myoclonic, or absence seizures.
- You cannot have used cannabis or CBD products (including Epidiolex) in the past 28 days or during the trial.
- Your weight must be between 44 lbs (20 kg) and 330 lbs (150 kg).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at EEG brain recordings in people with juvenile myoclonic epilepsy, especially those whose seizures started between ages 10 and 25. It may help researchers better understand how this epilepsy works and improve future care.
This trial tests adding zonisamide to the current epilepsy medication for children aged 1 to 14 who still have focal seizures. The goal is to see if the combination works better and is safe.
This trial tests a liquid medication called ZONISADE (zonisamide) for children aged 1 month to 17 years who have partial-onset seizures. It aims to see how the drug works in the body and how safe it is.
This trial tests a new medication called NPT 2042 for people with a type of epilepsy that causes brief staring spells (absence seizures). It aims to see if the drug can reduce seizure frequency compared to a placebo (an inactive pill).
This study tests an experimental pill called PRAX-628 for adults whose seizures are not fully controlled by current medications. It aims to see if the drug is safe and effective at reducing seizures.
This study tests a wearable device that records seizure-related information to understand how epilepsy affects daily life and safety. It may help your care team better track seizures in real-world settings and understand quality-of-life changes.
Hear when a new Juvenile Myoclonic Epilepsy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.